Download App

Log in to access Online Inquiry
Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

KNSA Kiniksa Pharmaceuticals

8.380-0.080-0.95%
Close 05/24 20:00 ET
High
8.530
Open
8.390
Turnover
1.06M
Low
8.120
Pre Close
8.460
Volume
126.91K
Market Cap
580.53M
P/E(TTM)
Loss
52wk High
16.679
Shares
69.28M
P/E(Static)
Loss
52wk Low
7.560
Float Cap
224.05M
Bid/Ask %
0.00%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
0.45
Historical Low
5.010
Dividend TTM
--
Div Yield TTM
35
P/B
3.49
Dividend LFY
--
Div Yield LFY
417.66%
Turnover Ratio
0.47%
Amplitude
4.85%
Avg Price
8.376
Lot Size
1
Float Cap
224.05M
Bid/Ask %
0.00%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
0.45
Historical Low
5.010
Dividend TTM
--
P/B
3.49
Dividend LFY
--
Turnover Ratio
0.47%
Amplitude
4.85%
Avg Price
8.376
Lot Size
1
Price Forecast

No Data

News

Comment